Ensysce Biosciences (ENSC) Enterprise Value (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Enterprise Value of -$4.6 million for Q4 2025, down 21.11% year-over-year from -$5.9 million in Q4 2024, and down 131.75% quarter-over-quarter from -$2.0 million in Q3 2025.
Ensysce Biosciences (ENSC) Enterprise Value (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Enterprise Value for 9 consecutive years, with -$4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value fell 21.11% year-over-year to -$4.6 million; the TTM figure through Dec 2025 stood at -$4.6 million (down 21.11% YoY), while the FY2025 annual figure was -$4.6 million, down 21.11% from the prior year.
- Enterprise Value retreated to -$4.6 million in Q4 2025 per ENSC's latest filing, from -$2.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$250000.0 in Q1 2021 and bottomed at -$12.5 million in Q4 2021.
- Historically, Enterprise Value has averaged -$4.6 million across 5 years, with a median of -$3.8 million in 2024.
- Annual changes were most pronounced in 2021 — Enterprise Value plunged 13220.26% — and 2023, when it jumped 80.11%.
- Ensysce Biosciences' Enterprise Value stood at -$12.5 million in 2021, then surged by 72.4% to -$3.5 million in 2022, then surged by 58.07% to -$1.5 million in 2023, then plunged by 163.81% to -$3.8 million in 2024, then decreased by 21.11% to -$4.6 million in 2025.
- Business Quant data shows ENSC's Enterprise Value at -$4.6 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | -4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.64 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Mar 31, 2025 | -3.38 Mn |
| Dec 31, 2024 | -3.83 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Mar 31, 2024 | -3.73 Mn |
| Dec 31, 2023 | -1.45 Mn |
| Sep 30, 2023 | -1.79 Mn |
| Jun 30, 2023 | -4.16 Mn |
| Mar 31, 2023 | -1.73 Mn |
| Dec 31, 2022 | -3.46 Mn |
| Sep 30, 2022 | -4.83 Mn |
| Jun 30, 2022 | -12.40 Mn |
| Mar 31, 2022 | -8.72 Mn |
| Dec 31, 2021 | -12.54 Mn |
| Sep 30, 2021 | -7.13 Mn |
| Jun 30, 2021 | -8.26 Mn |
| Mar 31, 2021 | -250,000.00 |